New Analyst Forecast: $GMAB Given 'Buy' Rating
HERVolution Appoints Dr. Tine Gaziel as CMO to Advance Dark Genome-Targeting Immune Therapy Into the Clinic
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $37
Genmab's Strong Market Position and Growth Potential Justifies Buy Rating
Genmab Advances Share Buy-back Program With Significant Repurchases
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Geron (GERN), Genmab (GMAB) and Elanco Animal Health (ELAN)
Express News | Genmab : Leerink Partners Raises Target Price to $29 From $27
Demonstrating resilience under Trump's tariff threats, Johnson & Johnson (JNJ.US) raises its full-year revenue guidance.
Johnson & Johnson announced its financial results for the first quarter.
Genmab Announces Net Sales of DARZALEX (Daratumumab) for First Quarter of 2025
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Top Gap Ups and Downs on Thursday: AU, KMX, HMY and More
6-K: Report of foreign private issuer (related to financial reporting)
Genmab A/S Share Capital Reduction
Genmab Analyst Ratings
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $37
Genmab Price Target Lowered to $37 From $50 at H.C. Wainwright
Genmab's Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
Genmab A/S Advances Share Buy-back Program as of April 2025
Is Genmab A/S (GMAB) D The Most Profitable Biotech Stock To Buy Right Now?